IDIOPATHIC PULMONARY FIBROSIS (IPF)

Drug development companies are regularly contacting us to take part in new clinical trials for improved IPF treatments, and we are keen to do so, as this provides Western Australians with IPF the opportunity to access new treatments.

If you suffer from IPF and would like to be considered for enrolment for participation in a clinical trials, please contact us by telephoning 9346 4964, email This e-mail address is being protected from spambots. You need JavaScript enabled to view it or click here to register online.

Study outline

Recruitment status

PIPF-016 - A year long study to to measure the potential benefits and the safety of treatment with Pirfenidone, a medication which is said to have anti-inflammatory and ant fibrotic actions. This medication is already approved in some countries other than Australia.
The medication is a tablet taken 3 times a day, with 14 visits over approx 14 months.
This is an international study. This study also offers patients the chance to participate in an open label extension program at the conclusion of the study.

Recruiting closed